Teresa Cortellino
Advertisement
Articles by Teresa Cortellino
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion
2
Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks
3
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
4
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
5